Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Translational medicine: mitigating risks for investigators

Nature Reviews Drug Discovery volume 12, pages 327–328 (2013)Cite this article

Subjects

Academic biomedical scientists are increasingly being encouraged to engage in translational research. However, there are underappreciated downsides for investigators if their translational efforts do not lead to positive results in pivotal clinical trials.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Talwar, K. K. et al. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J. Cardiac. Fail. 2, 273–277 (1996).

    Article  CAS  Google Scholar 

  2. Mochly-Rosen, D. & Grimes, K. V. Myocardial salvage in acute myocardial infarction — challenges in clinical translation. J. Mol. Cell Cardiol. 51, 451–453 (2011).

    Article  CAS  Google Scholar 

  3. Dimasi, J. A. et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).

    Article  CAS  Google Scholar 

  4. Ghofrani, H. A., Osterloh, I. H. & Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Rev. Drug Discov. 5, 689–702 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology and at the Department of Medicine, Douglas L. Mann is at the Center for Cardiovascular Research, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8086, St Louis, Missouri 63110, USA.,

    Douglas L. Mann

  2. Daria Mochly-Rosen is at the Department of Chemical and Systems Biology and at the School of Medicine, Stanford University, Stanford, California 94305, USA.,

    Daria Mochly-Rosen

Authors
  1. Douglas L. Mann
    View author publications

    Search author on:PubMed Google Scholar

  2. Daria Mochly-Rosen
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Douglas L. Mann.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

About the NIH Roadmap

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mann, D., Mochly-Rosen, D. Translational medicine: mitigating risks for investigators. Nat Rev Drug Discov 12, 327–328 (2013). https://doi.org/10.1038/nrd4005

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4005

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research